TIAA CREF Investment Management’s vTv Therapeutics VTVT Stock Holding History

TIAA CREF Investment Management’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-377	Closed	-$61K	–	3119
2018 Q1	$61K	Hold	377	–	–	﹤0.01%	3025
2017 Q4	$91K	Sell	377 -39	-9%	-$8.74K	﹤0.01%	3047
2017 Q3	$100K	Hold	416	–	–	﹤0.01%	3071
2017 Q2	$83K	Hold	416	–	–	﹤0.01%	3108
2017 Q1	$109K	Sell	416 -22	-5%	-$5.02K	﹤0.01%	3037
2016 Q4	$85K	Hold	438	–	–	﹤0.01%	3090
2016 Q3	$126	Hold	438	–	–	﹤0.01%	3079
2016 Q2	$102K	Buy	438 +302	+222%	+$69.5K	﹤0.01%	3131
2016 Q1	$28K	Hold	136	–	–	﹤0.01%	3077
2015 Q4	$37K	Buy	+136	New	+$38.2K	﹤0.01%	3135

Other funds holding VTVT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

TIAA CREF Investment Management's VTVT Position: Q2 2018 in Review

TIAA CREF Investment Management sold out of vTv Therapeutics (VTVT) in Q2 2018, closing a stake of 377 shares — an estimated $61K sold.

TIAA CREF Investment Management first reported a position in VTVT in Q4 2015 and held it in 10 quarters. The position peaked at $109K in Q1 2017. 27 funds tracked by Wall St. Rank hold VTVT as of Q2 2018.

TIAA CREF Investment Management reported no remaining vTv Therapeutics position as of Q2 2018 after selling out during the quarter.
TIAA CREF Investment Management sold 377 vTv Therapeutics shares in Q2 2018, an estimated $61K.
TIAA CREF Investment Management first reported a position in vTv Therapeutics in Q4 2015 and held it in 10 quarters.
TIAA CREF Investment Management's vTv Therapeutics position peaked at $109K in Q1 2017.
27 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2018.

Based on TIAA CREF Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.